613 related articles for article (PubMed ID: 32476490)
1. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.
Kittleson MM; Maurer MS; Ambardekar AV; Bullock-Palmer RP; Chang PP; Eisen HJ; Nair AP; Nativi-Nicolau J; Ruberg FL;
Circulation; 2020 Jul; 142(1):e7-e22. PubMed ID: 32476490
[TBL] [Abstract][Full Text] [Related]
2. Cardiac transthyretin amyloidosis.
Dungu JN; Anderson LJ; Whelan CJ; Hawkins PN
Heart; 2012 Nov; 98(21):1546-54. PubMed ID: 22888163
[TBL] [Abstract][Full Text] [Related]
3. [Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis)].
Tereshchenko SN; Zhirov IV; Moiseeva OM; Adasheva TV; Ansheles AA; Barbarash OL; Galyavich AS; Gudkova AI; Zateyshchikov DA; Kostareva AA; Nasonova SN; Nedogoda SV; Pecherina TB; Ryzhkova DV; Sergienko VB
Ter Arkh; 2022 May; 94(4):584-595. PubMed ID: 36286812
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Ruberg FL; Maurer MS
JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases.
Park GY; Jamerlan A; Shim KH; An SSA
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31216785
[TBL] [Abstract][Full Text] [Related]
6. Complexities and Pitfalls in Cardiac Amyloidosis.
Cuddy SAM; Dorbala S; Falk RH
Circulation; 2020 Jul; 142(4):409-415. PubMed ID: 32718247
[No Abstract] [Full Text] [Related]
7. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
8. Transthyretin-related amyloidoses and the heart: a clinical overview.
Rapezzi C; Quarta CC; Riva L; Longhi S; Gallelli I; Lorenzini M; Ciliberti P; Biagini E; Salvi F; Branzi A
Nat Rev Cardiol; 2010 Jul; 7(7):398-408. PubMed ID: 20479782
[TBL] [Abstract][Full Text] [Related]
9. Advances in the Treatment of Cardiac Amyloidosis.
Macedo AVS; Schwartzmann PV; de Gusmão BM; Melo MDT; Coelho-Filho OR
Curr Treat Options Oncol; 2020 Apr; 21(5):36. PubMed ID: 32328845
[TBL] [Abstract][Full Text] [Related]
10. Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy.
Fontana M; Porcari A; Hawkins PN
Glob Heart; 2023; 18(1):63. PubMed ID: 38028963
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types.
Varga C; Dorbala S; Lousada I; Polydefkis MJ; Wechalekar A; Maurer MS; Comenzo RL
Blood Rev; 2021 Jan; 45():100720. PubMed ID: 32616304
[TBL] [Abstract][Full Text] [Related]
12. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.
Yamamoto H; Yokochi T
ESC Heart Fail; 2019 Dec; 6(6):1128-1139. PubMed ID: 31553132
[TBL] [Abstract][Full Text] [Related]
13. Cardiac Care of Patients with Cardiac Amyloidosis.
Itzhaki Ben Zadok O; Kornowski R
Acta Haematol; 2020; 143(4):343-351. PubMed ID: 32408301
[TBL] [Abstract][Full Text] [Related]
14. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
[TBL] [Abstract][Full Text] [Related]
15. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
[TBL] [Abstract][Full Text] [Related]
16. Current and Evolving Multimodality Cardiac Imaging in Managing Transthyretin Amyloid Cardiomyopathy.
Alwan L; Benz DC; Cuddy SAM; Dobner S; Shiri I; Caobelli F; Bernhard B; Stämpfli SF; Eberli F; Reyes M; Kwong RY; Falk RH; Dorbala S; Gräni C
JACC Cardiovasc Imaging; 2024 Feb; 17(2):195-211. PubMed ID: 38099914
[TBL] [Abstract][Full Text] [Related]
17. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy.
Vaishnav J; Brown E; Sharma K
Prog Cardiovasc Dis; 2024; 82():113-124. PubMed ID: 38246305
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Rubin J; Maurer MS
Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
[TBL] [Abstract][Full Text] [Related]
19. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis.
Fine NM; Davis MK; Anderson K; Delgado DH; Giraldeau G; Kitchlu A; Massie R; Narayan J; Swiggum E; Venner CP; Ducharme A; Galant NJ; Hahn C; Howlett JG; Mielniczuk L; Parent MC; Reece D; Royal V; Toma M; Virani SA; Zieroth S
Can J Cardiol; 2020 Mar; 36(3):322-334. PubMed ID: 32145862
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society.
Grzybowski J; Podolec P; Holcman K; Gawor-Prokopczyk M; Jankowska E; Kostkiewicz M; Dąbrowska-Kugacka A; Lipowska M; Mazurkiewicz Ł; Rajtar-Salwa R; Rubiś P; Straburzyńska-Migaj E; Szczygieł J; Mitkowski P
Kardiol Pol; 2023; 81(11):1167-1185. PubMed ID: 37768101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
